Optimal Therapeutic Intervention Timepoints for siRNA-Based Huntington's Disease Therapies
Е-мейл Оргкомітету: firstname.lastname@example.org
Організатори: Creative Biolabs
Умови участі та проживання: 0
Gene therapy is at the forefront of medicine that utilizes genetic materials to treat or prevent diseases, including neurodegenerative diseases such as Huntington’s disease (HD). While dysregulation of dopamine transmission plays a key role in HD, little is known about the relationship between dopamine and the principal cause of HD, the production of mutant huntingtin protein due to the limitation on visualization of dopamine dynamics at the spatiotemporal resolution of both neuromodulator release (milliseconds) and boutons (microns).
Creative Biolabs has invited Dr. Markita Landry to walk us through how her team developed a near Infrared Catecholamine nanosensor (nIRCat) and used real-time imaging to find out what drives late-disease decreases in evoked dopamine release, and how to use these findings as optimal therapeutic intervention timepoints for siRNA-based HD therapies.
During this webinar, we will discuss the following key points:
- The development of nIRCat that can be used to image “hot spots” of dopamine activity in the striatum of R6/2 HD model mice
- How to use the findings as optimal therapeutic intervention timepoints for siRNA-based HD therapies
- How dopaminergic projections are affected by mutant huntingtin, and whether specific targeting of these loci is important for developing gene therapy efforts